Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.39 USD
Change Today -0.68 / -2.51%
Volume 1.3M
MDCO On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$27.00
Previous Close
$27.07
Day High
$27.44
Day Low
$26.38
52 Week High
03/20/15 - $32.44
52 Week Low
10/14/14 - $19.92
Market Cap
1.7B
Average Volume 10 Days
907.2K
EPS TTM
$-0.59
Shares Outstanding
66.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize ALN-PCSsc. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

727 Employees
Last Reported Date: 03/2/15
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $874.6K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $642.6K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $393.8K
Compensation as of Fiscal Year 2014.

medicines company (MDCO) Key Developments

The Medicines Company Announces FDA Approval of RAPLIXA™

The Medicines Company announced the U.S. Food and Drug Administration (FDA) has approved RAPLIXA™ (fibrin sealant) and the RaplixaSpray™ device to provide adjunctive hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature and cautery) is ineffective or impractical. According to IMS data, it is estimated that every year, approximately 2.6 – 3 million surgical procedures require the use of a topical hemostat product in the U.S. RAPLIXA requires no thawing, reconstitution, or mixing and can be applied either directly from the vial or with the RaplixaSpray™ device. The device is a low-pressure spray applicator designed to deliver RAPLIXA to larger bleeding surfaces in difficult to reach areas. The approval of RAPLIXA was based on one large Phase 3, multicenter clinical trial involving 721 patients in four countries. This trial demonstrated that RAPLIXA used in conjunction with an absorbable gelatin sponge was superior in achieving hemostasis as compared to treatment with sponge alone when used as an adjunct to hemostasis in patients undergoing vascular, hepatic, spinal, and soft tissue surgery. Adverse events were generally similar between treatment groups and consistent with those observed in patients undergoing surgery.

The Medicines Company Announces FDA Approval of IONSYS for the Management of Acute Post-Operative Pain for Adult Patients in the Hospital

The Medicines Company announced that the U.S. Food and Drug Administration (FDA) has approved IONSYS (fentanyl iontophoretic transdermal system), the first needle-free, patient-controlled, pre-programmed fentanyl delivery system, for the short-term management of acute post-operative pain in adult patients requiring opioid analgesia in the hospital. IONSYS offers patients recovering from surgery in the hospital control over their analgesic dosing by pushing a button to dispense fentany transdermally via an imperceptible electrical current as needed for pain. IONSYS will only be administered to patients in hospitals enrolled in the IONSYS Risk Evaluation Mitigation Strategy (REMS) program and is not intended for home use. The goal of the IONSYS REMS is to mitigate the risk of respiratory depression resulting from accidental exposure to persons for whom it is not prescribed.

The Medicines Company Proposes to Approve Amendment to its Third Amended and Restated Certificate of Incorporation

The Medicines Company proposed to approve amendment to its third amended and restated certificate of incorporation, as amended to date, to increase the number of authorized shares of common stock from 125,000,000 to 187,500,000 at its AGM to be held on May 28, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $26.39 USD -0.68

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 732.50 GBp -1.50
CryoLife Inc $10.18 USD +0.09
Integra LifeSciences Holdings Corp $65.34 USD -0.14
Krka dd Novo mesto €68.02 EUR -0.23
Skyepharma PLC 281.00 GBp +3.00
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.